QIAGEN (QGEN)
(Delayed Data from NYSE)
$43.73 USD
+0.56 (1.30%)
Updated May 24, 2024 04:00 PM ET
After-Market: $43.75 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.73 USD
+0.56 (1.30%)
Updated May 24, 2024 04:00 PM ET
After-Market: $43.75 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.
Abbott-North West London Pathology Expand in Diagnostics
by Zacks Equity Research
Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.
QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View
by Zacks Equity Research
QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.
QIAGEN Strengthens Cancer Research Foothold on New License
by Zacks Equity Research
QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.
Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo
by Zacks Equity Research
Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.
QIAGEN & Bristol-Myers Squibb Partner on Cancer Research
by Zacks Equity Research
QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.
Qiagen Banks on Molecular Diagnostic amid Currency Woes
by Zacks Equity Research
On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).
QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View
by Zacks Equity Research
QIAGEN N.V. (QGEN) reported first-quarter 2017 adjusted earnings per share (considering restructuring expenses as one time item) of 22 cents, up 15.8% year over year.
Qiagen (QGEN) Down 2.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN Releases Favorable GeneReader Results, Expands in NGS
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.
QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics
by Zacks Equity Research
QIAGEN N.V. (QGEN) launched ipsogen JAK2 RGQ PCR Kit in the U.S, following the Food and Drug Administration's (FDA) approval.
QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4
by Zacks Equity Research
QIAGEN N.V. (QGEN) reported fourth-quarter 2016 adjusted earnings per share (excluding restructuring expenses) of 39 cents, up 7.7% year over year.
QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.
Qiagen Poised on Fundamentals, Expansion Plans on Track
by Zacks Equity Research
On Dec 23, 2016, we issued an updated research report on Netherlands-based molecular diagnostics provider Qiagen NV (QGEN).